DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,046 filers reported holding DANAHER CORPORATION in Q3 2016. The put-call ratio across all filers is 0.17 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $198,480 | -75.3% | 800 | -76.1% | 0.13% | -72.3% |
Q2 2023 | $802,560 | -4.8% | 3,344 | 0.0% | 0.46% | -6.3% |
Q1 2023 | $842,822 | -2.1% | 3,344 | +3.1% | 0.49% | -3.2% |
Q4 2022 | $861,022 | +1.2% | 3,244 | -1.5% | 0.50% | -2.5% |
Q3 2022 | $851,000 | +1.9% | 3,294 | 0.0% | 0.52% | +7.9% |
Q2 2022 | $835,000 | -13.6% | 3,294 | 0.0% | 0.48% | -1.2% |
Q1 2022 | $966,000 | +1.5% | 3,294 | +13.8% | 0.49% | +7.0% |
Q4 2021 | $952,000 | +16.4% | 2,894 | +7.7% | 0.45% | +0.9% |
Q3 2021 | $818,000 | +39.4% | 2,687 | +22.9% | 0.45% | +42.9% |
Q2 2021 | $587,000 | +19.3% | 2,187 | 0.0% | 0.32% | +11.7% |
Q1 2021 | $492,000 | +1.2% | 2,187 | 0.0% | 0.28% | +1.8% |
Q4 2020 | $486,000 | +3.2% | 2,187 | 0.0% | 0.28% | -4.5% |
Q3 2020 | $471,000 | +37.3% | 2,187 | +12.9% | 0.29% | +30.6% |
Q2 2020 | $343,000 | +28.0% | 1,937 | 0.0% | 0.22% | +9.4% |
Q1 2020 | $268,000 | -23.2% | 1,937 | -14.9% | 0.20% | -7.7% |
Q4 2019 | $349,000 | +22.0% | 2,277 | +15.2% | 0.22% | +14.0% |
Q3 2019 | $286,000 | +0.7% | 1,977 | -0.7% | 0.19% | -0.5% |
Q2 2019 | $284,000 | +8.0% | 1,990 | 0.0% | 0.19% | +2.1% |
Q1 2019 | $263,000 | +30.8% | 1,990 | +1.9% | 0.19% | +13.8% |
Q4 2018 | $201,000 | -5.2% | 1,952 | 0.0% | 0.17% | +15.2% |
Q3 2018 | $212,000 | +9.8% | 1,952 | 0.0% | 0.14% | +1.4% |
Q2 2018 | $193,000 | +1.0% | 1,952 | 0.0% | 0.14% | +7.5% |
Q1 2018 | $191,000 | +5.5% | 1,952 | 0.0% | 0.13% | +12.7% |
Q4 2017 | $181,000 | +8.4% | 1,952 | 0.0% | 0.12% | +5.4% |
Q3 2017 | $167,000 | +1.2% | 1,952 | 0.0% | 0.11% | -0.9% |
Q2 2017 | $165,000 | -1.2% | 1,952 | -0.1% | 0.11% | -5.0% |
Q1 2017 | $167,000 | +9.9% | 1,953 | +0.1% | 0.12% | +5.3% |
Q4 2016 | $152,000 | -40.4% | 1,952 | -40.0% | 0.11% | -40.5% |
Q3 2016 | $255,000 | -4.9% | 3,252 | +22.6% | 0.19% | -5.0% |
Q2 2016 | $268,000 | +44.9% | 2,652 | +35.9% | 0.20% | +33.3% |
Q1 2016 | $185,000 | +46.8% | 1,952 | +44.4% | 0.15% | +47.1% |
Q4 2015 | $126,000 | +869.2% | 1,352 | +789.5% | 0.10% | +827.3% |
Q3 2015 | $13,000 | – | 152 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |